We collaborate with other databases and experts in multi-country database studies under the principles of the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP). We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We have registered studies in the EU PAS register, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.
The SIGMA Consortium is a contract-based alliance of European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) research centres with proven institutional pharmacoepidemiologic and real-world evidence (PE/RWE) experience, providing a one-stop shop for research services. It is the best ‘go-to’ organisation for comprehensive and rigorous methodological research, launched to enable multi-country studies that use common analyses to study responses to treatments in large populations.
Specifically, the SIGMA Consortium conducts the following activities:
- Act as a trusted hub for the planning, design, contracting, analyses, delivery, interpretation and dissemination of European PE/RWE studies, providing a one-stop shop to entities that request research services.
- Provide training and education through participation in studies.
- Promote, conduct, and facilitate innovative methodological research
The vision of the SIGMA Consortium is to provide best evidence on the use, benefits and harms of medications, vaccines and devices to improve public health and patient care. Its mission is to provide trusted pharmacoepidemiologic and real-world evidence (PE/RWE) through a European federated professional network of excellence based on the ENCePP Code of Conduct.